6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      USP30 sets a trigger threshold for PINK1–PARKIN amplification of mitochondrial ubiquitylation

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A new inhibitor of the deubiquitylase USP30, an actionable target relevant to Parkinson’s Disease, is introduced and characterised for parameters related to mitophagy.

          Abstract

          The mitochondrial deubiquitylase USP30 negatively regulates the selective autophagy of damaged mitochondria. We present the characterisation of an N-cyano pyrrolidine compound, FT3967385, with high selectivity for USP30. We demonstrate that ubiquitylation of TOM20, a component of the outer mitochondrial membrane import machinery, represents a robust biomarker for both USP30 loss and inhibition. A proteomics analysis, on a SHSY5Y neuroblastoma cell line model, directly compares the effects of genetic loss of USP30 with chemical inhibition. We have thereby identified a subset of ubiquitylation events consequent to mitochondrial depolarisation that are USP30 sensitive. Within responsive elements of the ubiquitylome, several components of the outer mitochondrial membrane transport (TOM) complex are prominent. Thus, our data support a model whereby USP30 can regulate the availability of ubiquitin at the specific site of mitochondrial PINK1 accumulation following membrane depolarisation. USP30 deubiquitylation of TOM complex components dampens the trigger for the Parkin-dependent amplification of mitochondrial ubiquitylation leading to mitophagy. Accordingly, PINK1 generation of phospho-Ser65 ubiquitin proceeds more rapidly in cells either lacking USP30 or subject to USP30 inhibition.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          Mitochondrial Machineries for Protein Import and Assembly.

          Mitochondria are essential organelles with numerous functions in cellular metabolism and homeostasis. Most of the >1,000 different mitochondrial proteins are synthesized as precursors in the cytosol and are imported into mitochondria by five transport pathways. The protein import machineries of the mitochondrial membranes and aqueous compartments reveal a remarkable variability of mechanisms for protein recognition, translocation, and sorting. The protein translocases do not operate as separate entities but are connected to each other and to machineries with functions in energetics, membrane organization, and quality control. Here, we discuss the versatility and dynamic organization of the mitochondrial protein import machineries. Elucidating the molecular mechanisms of mitochondrial protein translocation is crucial for understanding the integration of protein translocases into a large network that controls organelle biogenesis, function, and dynamics.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy.

            Cells maintain healthy mitochondria by degrading damaged mitochondria through mitophagy; defective mitophagy is linked to Parkinson's disease. Here we report that USP30, a deubiquitinase localized to mitochondria, antagonizes mitophagy driven by the ubiquitin ligase parkin (also known as PARK2) and protein kinase PINK1, which are encoded by two genes associated with Parkinson's disease. Parkin ubiquitinates and tags damaged mitochondria for clearance. Overexpression of USP30 removes ubiquitin attached by parkin onto damaged mitochondria and blocks parkin's ability to drive mitophagy, whereas reducing USP30 activity enhances mitochondrial degradation in neurons. Global ubiquitination site profiling identified multiple mitochondrial substrates oppositely regulated by parkin and USP30. Knockdown of USP30 rescues the defective mitophagy caused by pathogenic mutations in parkin and improves mitochondrial integrity in parkin- or PINK1-deficient flies. Knockdown of USP30 in dopaminergic neurons protects flies against paraquat toxicity in vivo, ameliorating defects in dopamine levels, motor function and organismal survival. Thus USP30 inhibition is potentially beneficial for Parkinson's disease by promoting mitochondrial clearance and quality control.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity

              Alzheimer’s disease (AD) is a common and devastating disease characterized by the aggregation of amyloid-β peptide (Aβ), yet we know relatively little about the underlying molecular mechanisms or how to treat AD patients. Here, we provide bioinformatic and experimental evidence of a conserved mitochondrial stress response signature present in Aβ proteotoxic diseases in human, mouse and C. elegans, and which involves the UPRmt and mitophagy pathways. Using the worm model of Aβ proteotoxicity, GMC101, we recapitulated mitochondrial features and confirmed the induction of this mitochondrial stress response as key to maintain mitochondrial proteostasis and health. Importantly, boosting mitochondrial proteostasis by pharmacologically and genetically targeting mitochondrial translation and mitophagy increases fitness and lifespan of GMC101 worms and reduces amyloid aggregation in cells, worms, and in AD transgenic mice. Our data support the relevance of enhancing mitochondrial proteostasis to delay Aβ proteotoxic diseases, such as AD.
                Bookmark

                Author and article information

                Journal
                Life Sci Alliance
                Life Sci Alliance
                lsa
                lsa
                Life Science Alliance
                Life Science Alliance LLC
                2575-1077
                7 July 2020
                August 2020
                7 July 2020
                : 3
                : 8
                : e202000768
                Affiliations
                [1 ]Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK
                [2 ]Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
                [3 ]Alzheimer’s Research UK, Oxford Drug Discovery Institute, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
                [4 ]FORMA Therapeutics, Watertown, MA, USA
                [5 ]Chemical Genomics Centre, Max-Planck-Institute of Molecular Physiology, Dortmund, Germany
                [6 ]Department of Chemistry and Chemical Biology, Technische Universität Dortmund, Dortmund, Germany
                [7 ]Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK
                [8 ]Ubiquitin Signalling Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
                [9 ]Department of Medical Biology, University of Melbourne, Melbourne, Australia
                [10 ]Laboratory for Biological Mass Spectrometry, Newcastle University Biosciences Institute, Faculty of Medical Sciences, University of Newcastle, Newcastle, UK
                Author notes
                Correspondence: urbe@ 123456liv.ac.uk

                Christopher J Burke’s present address is Yumanity Therapeutics–Discovery Biology, Cambridge, MA, USA

                Alejandro Murad’s present address is Skyhawk Therapeutics, Neurobiology, Waltham, MA, USA

                Katherine J Kayser-Bricker’s present address is Halda Therapeutics, Branford, CT, USA

                Alexandre J Buckmelter’s present address is Morphic Therapeutic, Waltham, MA, USA

                Stephanos Ioannidis’s present address is H3 Biomedicine, Cambridge, MA, USA

                Michael K Ahlijanian’s present address is Pinteon Therapeutics, Newton, MA, USA

                [*]

                Emma V Rusilowicz-Jones and Jane Jardine contributed equally to this work

                Author information
                https://orcid.org/0000-0001-7496-3318
                https://orcid.org/0000-0002-7646-9636
                https://orcid.org/0000-0001-8771-963X
                https://orcid.org/0000-0002-7920-7877
                https://orcid.org/0000-0003-4382-9313
                https://orcid.org/0000-0003-1648-9448
                https://orcid.org/0000-0001-7840-2411
                https://orcid.org/0000-0001-6439-0579
                https://orcid.org/0000-0003-4735-9814
                https://orcid.org/0000-0003-3355-9479
                Article
                LSA-2020-00768
                10.26508/lsa.202000768
                7362391
                32636217
                09219fa1-2af5-4223-8913-5ed5b2b5706b
                © 2020 Rusilowicz-Jones et al.

                This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

                History
                : 7 May 2020
                : 25 June 2020
                : 26 June 2020
                Funding
                Funded by: Michael J. Fox Foundation, Alzheimer’s Research UK;
                Award Recipient :
                Funded by: Parkinson’s UK;
                Award ID: H-1502
                Award Recipient :
                Funded by: Medical Research Council;
                Award ID: MR/N00941X/1
                Award Recipient :
                Funded by: Wellcome Trust;
                Award Recipient :
                Funded by: European Union;
                Award Recipient :
                Categories
                Research Article
                Research Articles
                1
                4
                5

                Comments

                Comment on this article